Page last updated: 2024-08-23

lonidamine and Disease Exacerbation

lonidamine has been researched along with Disease Exacerbation in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (40.00)18.2507
2000's1 (20.00)29.6817
2010's2 (40.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Gallo, KA; Wu, X1
Boonmars, T; Cha'on, U; Phoomak, C; Sangkhamanon, S; Seubwai, W; Thamrongwaranggoon, U; Wongkham, S1
Alquati, P; Berruti, A; Bitossi, R; Bonazzi, G; Bottini, A; Bruzzi, P; Bumma, C; Castiglione, F; Danese, S; De Lena, M; De Matteis, A; DeFabiani, E; Dogliotti, L; Farris, A; Giardina, G; Gorzegno, G; Lorusso, V; Moro, G; Nuzzo, F; Sarobba, MG1
Carpano, S; Conti, F; Di Lauro, L; Giannarelli, D; Gionfra, T; Lopez, M; Paoletti, G; Pignatti, F; Vici, P1
Brancaccio, L; Carnicelli, P; Cioffi, R; Comella, P; De Cataldis, G; Ianniello, GP; Lombardi, A; Maiorino, A; Scarpati, MD; Tinessa, V1

Trials

3 trial(s) available for lonidamine and Disease Exacerbation

ArticleYear
Time to progression in metastatic breast cancer patients treated with epirubicin is not improved by the addition of either cisplatin or lonidamine: final results of a phase III study with a factorial design.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Oct-15, Volume: 20, Issue:20

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Disease Progression; Epirubicin; Female; Humans; Indazoles; Logistic Models; Middle Aged; Survival Analysis

2002
Intrapatient comparison of single-agent epirubicin with or without lonidamine in metastatic breast cancer.
    European journal of cancer (Oxford, England : 1990), 1995, Volume: 31A, Issue:10

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Drug Resistance, Neoplasm; Epirubicin; Female; Follow-Up Studies; Humans; Indazoles; Middle Aged; Neoplasm Metastasis; Survival Rate

1995
Cisplatin, epirubicin, and vindesine with or without lonidamine in the treatment of inoperable nonsmall cell lung carcinoma: a multicenter randomized clinical trial.
    Cancer, 1996, Jul-01, Volume: 78, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease Progression; Epirubicin; Female; Humans; Indazoles; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Vindesine

1996

Other Studies

2 other study(ies) available for lonidamine and Disease Exacerbation

ArticleYear
The 18-kDa translocator protein (TSPO) disrupts mammary epithelial morphogenesis and promotes breast cancer cell migration.
    PloS one, 2013, Volume: 8, Issue:8

    Topics: Acinar Cells; Apoptosis; Benzodiazepinones; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Size; Disease Progression; Humans; Indazoles; Isoquinolines; Ligands; Mammary Glands, Human; Neoplasm Invasiveness; Receptors, GABA

2013
Targeting hexokinase II as a possible therapy for cholangiocarcinoma.
    Biochemical and biophysical research communications, 2017, 03-04, Volume: 484, Issue:2

    Topics: Animals; Bile Duct Neoplasms; Cell Division; Cell Line, Tumor; Cholangiocarcinoma; Cricetinae; Disease Progression; Enzyme Inhibitors; Hexokinase; Immunohistochemistry; Indazoles; Opisthorchis

2017